This page is updated frequently with new Receptor-related patent applications.
| Device for displaying an image sequence and system for displaying a scene|
A device for displaying an image sequence in the form of a pixel matrix, includes a control unit coupled to a projector. The control unit includes an input interface designed to receive asynchronous information representing, for each pixel of the matrix, events concerning the pixel, and a processor designed to control the activation of each pixel of the matrix at moments determined by the respective events indicated by the asynchronous information for the pixel.
Centre National De La Recherche Scientifique - Cnrs
| Progressive compression driven flow cartridge for analyte detecting strip and method|
A cartridge and method for conducting a labeled molecular affinity binding test such as antibody/antigen, ligand/receptor, and colorometric reactions, and other chemical reactions for which one or more analytes is present in a liquid sample formate. A progressive compression structure progressively forces a liquid flow out of a conjugate pad toward a reaction region to more thoroughly and rapidly mix the liquid, encouraging specific first affinity binding to the analytes in question.
| Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase|
The present invention relates to a novel function of lysyl trna synthetase, that is, lysyl trna synthetase interacts with 67lr through translocation of krs into plasma membrane, and so enhances tumor (or cancer) cell migration, thereby having an effect on cancer metastasis. More specifically, it relates to method for controlling cancer metastasis or cancer cell migration by modulating an cellular level of lysyl trna synthetase, an use of an expression vector comprising a construct inhibiting krs expression for preventing or treating cancer, an use of an agent inhibiting krs activity for preventing or treating cancer, a method for screening an agent which modulates cancer metastasis or cancer cell migration, a method for screening an agent inhibiting an interaction between krs and 67lr.
Medicinal Bioconvergence Research Center
| Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors|
The present invention provides an hsv vector comprising an envelope comprising one or more mutant gb and/or gh envelope glycoproteins, whereby the hsv vector exhibits at least 25% increased rate-of-entry after 20 minutes when assayed at 30° c. Or 37° c.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
| Modulation of growth hormone receptor expression and insulin-like growth factor expression|
Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-i (igf-i). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor.
Antisense Therapeutics Limited
| Aptamer conjugates with n-heterocyclic carbene metal complexes for targeted drug delivery|
An aptamer-n-heterocyclic-carbene metal complex conjugate (aptamer-nhcm conjugate) or an aptamer-bis-n-heterocyclic-carbene metal complex conjugate (aptamer-bis-nhcm conjugate) includes an aptamer coupled through a hydrolytically stable bond to an n-heterocyclic-carbene metal complex (nhcm) or a bis-n-heterocyclic-carbene metal complex (bis-nhcm). The aptamer-nhcm conjugate is prepared where the chosen aptamer displays selective binding to a cell specific receptor, such that the cytotoxic nhcm can be directed specifically to cells responsible for a target disease (e.g., a specific cancer type).
University Of Florida Research Foundation, Inc.
| Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease|
The invention provides a chimeric receptor comprising nkg2d, dap10 and cd3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of nk cells.
National University Of Singapore
| Neutralizing antibodies and methods of use thereof|
This invention provides monoclonal antibodies that recognize the toll-like receptor 4/md-2 receptor complex, and monoclonal antibodies that recognize the tlr4/md2 complex as well as tlr4 when not complexed with md-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics.
| Antagonists for abdominal vasopressin v2 receptor and uses thereof|
Provided herein are antagonists or binding agents of an abnormal vasopressin receptor v2 (e.g., abnv2), such as antibodies and antigen-binding portions thereof specific for the receptor, for identifying and targeting cancer cells expressing such abnormal vasopressin receptor v2. Additionally provided are methods of using said antagonists or binding agents, for example, to image cancer cells or in biological samples, or diagnose cancers, both in vivo and in vitro.
Woomera Therapeutics, Inc
| Dual receptor antagonistic antigen-binding proteins and uses thereof|
This disclosure relates to antagonistic dual receptor antigen-binding proteins, e.g. Antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases.
Chimeric antigen receptors targeting cd-19
The invention is directed to a chimeric antigen receptor (car) directed against cd19, which comprises an amino acid sequence of any one of seq id no: 1-seq id no: 13. The invention also provides t-cells expressing the car and methods for destroying malignant b-cells..
Department Of Health And Human Services
Bispecific chimeric antigen receptors and encoding polynucleotides thereof
The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain fv (scfv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors..
Seattle Children's Hospital D/b/a Seattle Children's Research Institute
Insulin receptor partial agonists
Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.. .
Merck Sharp & Dohme Corp.
Azamorphinan derivatives and use thereof
The application is directed to compounds of formula (i) and pharmaceutically acceptable salts and solvates thereof, wherein r1, r2, r3, r4, y, and z are defined as set forth in the specification. The invention is also directed to use of compounds of any one of formulae i-viii, and the pharmaceutically acceptable salts and solvates thereof, to treat disorders responsive to the modulation of one or more opioid receptors, or as synthetic intermediates.
Purdue Pharma L.p.
The invention relates to compounds of formula (i) wherein r1, r2, r3, r4 and r5 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the cxcr3 receptor.. .
Actelion Pharmaceuticals Ltd
Trka kinase inhibitors, compositions and methods thereof
The present invention is directed to a bicyclic heteroaryl benzamide compounds of formula (i) which are tropomyosin-related kinase (trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (ngf) receptor trka.. .
Merck Sharp & Dohme Corp.
Article attachment assembly suitable for vehicle
An article attachment assembly includes a connector, and an insert to be connected to and rotate about the connector. The insert includes first and second walls connected to each other with an angle positioned there-between.
Ford Global Technologies, Llc
Method for producing artificial retina
There is provided a method for producing an artificial retina in which an organic dye compound that induces a receptor potential responding to photostimulation is fixed on a polymer sheet substrate, comprising a bonding step of immersing the substrate in a solution containing the organic dye compound to chemically bond the organic dye compound to the substrate; a first washing step of washing with water the substrate to which the organic dye compound has been chemically bonded; and a second washing step of, after the first washing step, washing with an organic solvent the substrate to which the organic dye compound has been chemically bonded. Thus, there can be provided an artificial retina which has excellent mechanical properties such as elongation at break and good biocompatibility, and is capable of inducing a receptor potential responding to photostimulation with high sensitivity..
National University Corporation Okayama University
Methods of treatment using anti-erbb antibody maytansinoid conjugates
The application concerns methods of treatment using anti-erbb receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns erbb receptor-directed cancer therapies, using anti-erbb receptor antibody-maytansinoid conjugates..
Delivery of therapeutic agents by a collagen binding protein
Methods of delivering therapeutic agents by administering compositions including a bacterial collagen-binding polypeptide segment linked to the therapeutic agent to subjects in need of treatment with the therapeutic agent are provided. Methods of treating hyperparathyroidism, and hair loss using compositions comprising a collagen binding polypeptide and a pth/pthrp receptor agonist are provided.
Montefiore Medical Center
Humanized anti-tau(ps422) antibody brain shuttles and use thereof
Herein is reported a non-covalent complex of a haptenylated antibody that specifically binds to human tau(ps422) and an anti-blood brain barrier receptor/hapten bispecific antibody.. .
Hoffmann-la Roche Inc.
Use of long-acting human recombinant soluble tumor necrosis factor a receptor in the preparation of drugs for preventing and treating severe liver injury on chronic liver disease
The proposed invention involves the use of new drugs with the recombinant soluble tumor necrosis α receptor (hustnfr) and belongs to the gene engineering technology and gene function application field. This invention uses type i or type ii long-acting hustnfr (lhustnfr) to perform an intervention for severe liver injury in rats with chronic liver disease using 5 types of animal models.
Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
Compounds and methods are provided for the treatment of, inter alia, type ii diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active..
Cymabay Therapeutics, Inc.
Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome
This application relates to methods of treating attention deficit hyperactivity disorder (adhd), 22q deletion and/or duplication syndrome, and co-morbidities with a nonselective activator of metabotropic glutamate receptors, such as fasoracetam, for example, in subjects having a genetic alteration in at least one metabotropic glutamate receptor (mglur) network gene.. .
The Children's Hospital Of Philadelphia
Methods for treating nicotinic acetylcholine receptor associated diseases
The present invention provides methods and compositions for treating subjects suffering from a disorder associated with a nicotinic acetylcholine receptor (nachr), methods for treating a subject having a disorder that would benefit from an increase in neural plasticity, and methods for modulating the plasticity of the primary visual cortex in subjects by modulating the expression, stability, and/or activity of lynx1.. .
President And Fellows Of Harvard College
Cenicriviroc for the treatment of hiv-2 infection
Cenicriviroc (cvc) is an orally active antagonist of ligand binding to c—c chemokine receptor type 5 (ccr5) and c—c chemokine receptor type 2 (ccr2). Cvc blocks the binding of rantes, mip-1α, and mip-1β to ccr5, and of mcp-1/ccl2 to ccr2.
Tobira Therapeutics, Inc.
Apparatus and fascial closure device for laparoscopic trocar port site and surgery
A suture placement device provides a lateral extension element, such as a slotted t-bar or wings, which is inserted into a trocar and deployed to position receptor ports about 1 cm from the trocar. The trocar is removed, and stylet guides are deployed to create a path from the housing to the receptor ports, thereby creating a suture path with segments from the outside of the device to each port, and between ports.
Lithium secondary battery
A lithium secondary battery includes an electrode assembly to which an electrode tap is attached, an electrode tap receptor configured to house a portion of the electrode assembly such that a portion of the electrode tap protrudes to an outside, and a case configured to surround the electrode assembly and seal the electrode assembly together with the electrode tap receptor, wherein the electrode tap receptor includes a gas barrier layer.. .
Sk Innovation Co., Ltd.
Organic solar cell and preparation method thereof
An organic solar cell device is provided, including a first electrode, a photoactive layer, a hole transport layer, and a second electrode that are stacked successively. The photoactive layer includes an electron receptor material and an electron donor material.
Huawei Technologies Co., Ltd.
Image forming apparatus
In an image forming apparatus, a cleaning portion has a discharge pipe that guides toner that has been collected from a peripheral surface of a photoreceptor drum as waste toner to the outside of a process unit. The discharge pipe is drawn from a side surface of the process unit and includes at a tip portion a discharge port that discharges the waste toner.
Sharp Kabushiki Kaisha
Electrophotographic photoreceptor, process cartridge, and electrophotographic apparatus
An electrophotographic photoreceptor abuts against a charging member and/or a developer carrying member with an abutting member therebetween, has a first portion and a second portion abutting against the abutting member along the longitudinal direction of the photoreceptor, and includes a support, a charge generating layer containing a charge generation material, and a surface layer in this order. The first portion includes an undercoat layer containing a polymer of a composition containing an electron transport material and a crosslinking agent and being contiguous with the surface of the charge generating layer facing the support.
Canon Kabushiki Kaisha
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
The present invention is directed to methods of using biomarkers to assess treatment of gastrointestinal inflammatory disorders with beta7 antagonists. More particularly, the present invention relates to methods of using the level of gut-homing lymphocytes in peripheral blood, the level of drug occupancy on gut-homing lymphocytes, and/or the level of beta7 integrin receptors on gut-homing lymphocytes as indicators (or biomarkers) of the effect, efficacy, safety, prognosis, and/or dosing of therapeutic agents, such as beta7 integrin antagonists, for the treatment of gastrointestinal inflammatory disorders..
Two-dimensional material-based field-effect transistor sensors
Atomically layered transition metal dichalcogenides (tmdcs) exhibit a significant potential to enable low-cost transistor biosensors that permit single-molecule-level quantification of biomolecules. Two different principles for operating such biosensors are presented.
The Regents Of The University Of Michigan
Electrochemical sensor for analyte detection
A sensor for the detection of an analyte in a biological sample includes a substrate, a working electrode and counter electrode formed on a surface of the substrate, and a receptor functionalized or chemically functionalized to a surface of an exposed portion of the working electrode. The receptor can selectively bind to the analyte of interest and the analyte once bound is detectable by measuring the current flow between the working electrode and counter electrode..
Case Western Reserve University
Novel pharmaceutical compositions comprising an antibody which binds the human anti-mÜllerian hormone receptor type ii
The invention relates to novel pharmaceutical compositions including, as active ingredient, an antibody binding the human anti-müllerian hormone type ii receptor (amhr-ii) and an anticancer agent, as well as the therapeutic applications of these compositions.. .
Universite Montpellier 1
Antigen-binding proteins that activate the leptin receptor
The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (lepr), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind lepr and activate lepr signaling.
Regeneron Pharmaceuticals, Inc.
Chemokine receptor binding polypeptides
The present invention relates to polypeptides directed against or specifically binding to chemokine receptor cxcr2 and in particular to polypeptides capable of modulating signal transduction from cxcr2. The invention also relates to nucleic acids, vectors and host cells capable of expressing the polypeptides of the invention, pharmaceutical compositions comprising the polypeptides and uses of said polypeptides and compositions for treatment of diseases involving aberrant functioning of cxcr2..
Synthetic antibody mimic peptides
The present disclosure relates to compositions and methods comprising peptide molecules that mimic the binding and functional properties of native antibodies relative to their respective targets. Some embodiments comprise peptide-drug conjugates (pdcs) comprising the mimic peptides disclosed herein.
Ldlr variants and their use in compositions for reducing cholesterol levels
A recombinant vector having an expression cassette is provided which comprises a modified human low density lipoprotein receptor (hldlr) gene is provided, wherein said hldlr gene encodes a modified hldlr comprising (a) one or more of the following amino acid substitutions: l318h, n295d, h306d, v307d, n309a, d310n, l318h, and/or l318d; or (b) an amino acid substitution of any of (a) in combination with one or more of the following amino acid substitutions: k796, k809r and/or c818a. Also provided are pharmaceutical compositions containing this vector and uses therefor in lowering cholesterol and/or treating familial hypercholesterolemia..
The Trustees Of The University Of Pennsylvania
Fusion proteins of collagen-binding domain and parathyroid hormone
Fusion proteins containing active agonist or antagonist fragments of parathyroid hormone (pth) and parathyroid hormone related peptide (pthrp) coupled to a collagen-binding domain are presented. The fusion proteins can be used to promote bone growth, to promote hair growth, to prevent cancer metastasis to bone, to promote immune reconstitution with a bone marrow stem cell transplant, to promote mobilization of bone marrow stem cells for collection for autologous stem cell transplant, and to treat renal osteodystrophy.
The Board Of Trustees Of The University Of Arkansas
Long-acting insulin and use thereof
The present invention relates to an insulin analog that has reduced insulin receptor binding affinity for the purpose of increasing the blood half-life of insulin, and long-acting insulin, a conjugate, and a method of preparing long-acting insulin using the same.. .
Hanmi Pharm. Co., Ltd.
Glp-1/glucagon receptor co-agonists for medical use
The present invention relates to novel glucagon derivatives which are glp-1/glucagon receptor co-agonists, and to the use of said glucagon derivatives in medicine, such as in the treatment of diabetes, obesity and related diseases and conditions.. .
Novo Nordisk A/s
Modulating gamma-c-cytokine activity
Embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Chimeric fibroblast growth factor 19 proteins and methods of use
The present invention relates to a chimeric protein that includes an n-terminus coupled to a c-terminus, where the n-terminus includes a portion of a paracrine fibroblast growth factor (“fgf”) and the c-terminus includes a c-terminal portion of an fgf 19 molecule. The portion of the paracrine fgf is modified to decrease binding affinity for heparin and/or heparan sulfate compared to the portion without the modification.
New York University
Peptide ligands for hepatic stellate cells
Methods and compositions for identifying and using polypeptides that target hepatic stellate cells are described. Embodiments include a targeting composition that may include one or more polypeptides including an amino acid sequence that binds to an insulin-like growth factor 2 receptor.
Farnesoid x receptor modulators
Or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof, wherein r1-r10, m, n, p, and are as described herein. The present invention relates generally to fxr modulators and to methods of making and using said compounds..
Alkyl and aryl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
The present invention relates to compounds of general formula (i) having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opiod receptor and more particularly to diazaspiro undecane compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain.. .
Laboratorios Del Dr. Esteve S.a.
Difluoroethylpyridine derivatives as nr2b nmda receptor antagonists
Disclosed are chemical entities of formula (i) wherein x, y, z, r1, r3, r4, r5 and r6 are defined herein, as nr2b subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of formula (i), and methods of treating various diseases and disorders associated with nr2b antagonism, e.g., diseases and disorders of the cns, such as depression, by administering a chemical entity of formula i..
Rugen Holdings (cayman) Limited
Substituted prolines / piperidines as orexin receptor antagonists
The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease..
Eolas Therapeutics, Inc.
The present invention relates to novel retinoid-related orphan receptor gamma (rorγ) modulators and their use in the treatment of diseases mediated by rorγ. .
Glaxosmithkline Intellectual Property Development Limited
Androgen receptor antagonists
Disclosed herein are compositions and methods for modulating the androgen receptor.. .
The Regents Of The University Of California
Sweetness receptor antagonist
Wherein each symbol is described herein, are useful for the prophylaxis or treatment of metabolic syndrome, diabetes, obesity and the like.. .